Bayer Ag ADR (OP:BAYRY)

12.64 -0.09 (-0.71%)

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Bayer: Aspirin To Crop Protection ↗

December 18, 2022

Pharmaceutical drugs account for 41% of Bayer's revenues and include Xarelto, Eylea, Mirena, Kogenate and Nexavar. Its OTC product lineup is filled with household names like Aleve, Alka Seltzer,...

Via Talk Markets

Current Report: Bayer AG ↗

November 17, 2022

By my dogcatcher ideal, this may be a prime time to buy Bayer AG shares based on their dividends for the coming year 2022-23.

Via Talk Markets

Ionis Regains Rights To Thrombosis Candidate From Bayer ↗

November 04, 2022

Via Benzinga

Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher? ↗

October 20, 2022

It seems that Ginkgo Bioworks is announcing a new acquisition or collaboration every day this month, putting DNA stock in focus.

Via InvestorPlace

What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today? ↗

October 18, 2022

AVEO stock jumped on the news that LG Chem will pay $15/share for Aveo Oncology and make it the centerpiece of a new oncology division.

Via InvestorPlace

Elon Musk Renews Twitter's Buyout Proposal, Apple Suppliers Working On Cutting China Reliance, E-Cigarette Maker Considers Bankruptcy: Top Stories Wednesday, Oct. 5 ↗

October 05, 2022

Wall Street Journal

Via Benzinga

Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death ↗

August 29, 2022

Via Benzinga

Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration ↗

August 18, 2022

Via Benzinga

Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor ↗

October 05, 2022

Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup...

Via Benzinga

Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More... ↗

September 14, 2022

Reuters

Via Benzinga

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report ↗

September 14, 2022

Via Benzinga

BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors ↗

September 12, 2022

Via Benzinga

FDA Approves Expanded Use For Bayer's Prostate Cancer Drug ↗

August 08, 2022

Via Benzinga

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics ↗

May 23, 2022

Via Benzinga

Deere Invests Billions In Self-Driving Tractors, Smart Crop Sprayers: Report ↗

September 12, 2022

Via Benzinga

Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug ↗

September 08, 2022

Via Benzinga

7 Stocks Under $15 to Buy and Hold Forever ↗

September 01, 2022

For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.

Via InvestorPlace

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops ↗

August 29, 2022

The companies hoped to reduce the risk of myriad complications for at-risk patients.

Via Investor's Business Daily

This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence ↗

July 27, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,...

Via Benzinga

Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today? ↗

July 25, 2022

DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site.

Via InvestorPlace

Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages ↗

June 29, 2022

(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.)

Via Benzinga

BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products ↗

June 27, 2022

Via Benzinga

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗

June 13, 2022

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.

Via Benzinga

7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend ↗

June 08, 2022

These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250.

Via InvestorPlace

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off ↗

June 01, 2022

Via Benzinga

Three Stocks To Buy In This Bear Market ↗

May 30, 2022

There’s a silver lining to the current bear market. It’s created great buying opportunities.

Via Talk Markets

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Via Benzinga

How Heart Drugs Could Pump $10 Billion Into Merck's Coffers ↗

May 19, 2022

As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.